| Stereochemistry | ACHIRAL |
| Molecular Formula | C20H15ClFN5O5S2 |
| Molecular Weight | 523.945 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CNC1=CC2=C(C=C1F)C(=O)N(C(=O)N2)C3=CC=C(NC(=O)NS(=O)(=O)C4=CC=C(Cl)S4)C=C3
InChI
InChIKey=LGSDFTPAICUONK-UHFFFAOYSA-N
InChI=1S/C20H15ClFN5O5S2/c1-23-15-9-14-12(8-13(15)22)18(28)27(20(30)25-14)11-4-2-10(3-5-11)24-19(29)26-34(31,32)17-7-6-16(21)33-17/h2-9,23H,1H3,(H,25,30)(H2,24,26,29)
| Molecular Formula | C20H15ClFN5O5S2 |
| Molecular Weight | 523.945 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Elinogrel, previously known as PRT060128 or PRT128, is a direct-acting, reversible P2Y12 inhibitor for both intravenous and oral administration. Elinogrel has been tested in 2 phase II studies for the treatment of acute coronary syndrome, myocardial infarction and prevention of secondary thrombotic events. Elinogrel therapy was associated with an increased incidence of dyspnea and incidence of elevated liver transaminases. The development of the drug was terminated in January 2012 by Novartis.
Originator
Approval Year
Doses
AEs
Sourcing
PubMed
Patents
Sample Use Guides
80-mg intravenous bolus of elinogrel was given immediately before percutaneous coronary intervention, followed by twice-daily oral elinogrel administration of 50, 100, or 150 mg for 60 days
Route of Administration:
Other
